Nutra Pharma Begins Marketing Nyloxin™ Through Direct Distributors

Nutra Pharma announces the direct distribution of their Nyloxin™ line of pain relievers through TCN, a network of distributors in more than 20 countries.

September 20, 2012 -- Coral Springs, Florida -- Nutra Pharma Corporation (Pink Sheets: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have begun selling Nyloxin through the TCN group of direct distributors.

“We are excited to be working with TCN to aggressively market and sell Nyloxin,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “TCN distributors have been working with us over the past few months to roll out Nyloxin to approximately 40,000 distributors in the United States and almost 400,000 distributors globally,” he concluded.

Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.  Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

“The Nyloxin products represent a wonderful opportunity for our distributors,” commented Dalton Johnson, CEO of TCN. “These are pain-relievers and anti-inflammatory drugs that have provided great results with almost no risk of side effects. We believe that we can potentially achieve significant sales through our distributors as well as sales continuity as they use and order the product monthly," he concluded.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The distribution of Nyloxin through TCN should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

# # #

Contact:
Nutra Pharma Corp.
Nina Goldstein
877-895-5647
IR@nutrapharma.com

Tags: